Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8,227 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase (ALK) rearrangements and co-existing alterations-a retrospective cohort study.
Li J, Huang K, Ji H, Qian J, Lu H, Zhang Y, Russo A, Romero A, Urbanska EM, Tabbò F, Zhao X, Chu T. Li J, et al. Among authors: qian j. Transl Lung Cancer Res. 2023 Dec 26;12(12):2505-2519. doi: 10.21037/tlcr-23-658. Epub 2023 Nov 22. Transl Lung Cancer Res. 2023. PMID: 38205204 Free PMC article.
Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients.
Cui S, Zhao Y, Dong L, Gu A, Xiong L, Qian J, Zhang W, Niu Y, Pan F, Jiang L. Cui S, et al. Among authors: qian j. Cancer Med. 2016 Jun;5(6):1013-21. doi: 10.1002/cam4.659. Epub 2016 Feb 16. Cancer Med. 2016. PMID: 26880708 Free PMC article.
First-line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non-squamous non-small cell lung cancer with wild-type driver genes: A real-world study in China.
Chang Q, Zhang Y, Xu J, Zhong R, Qiang H, Zhang B, Han B, Qian J, Chu T. Chang Q, et al. Among authors: qian j. Thorac Cancer. 2019 May;10(5):1043-1050. doi: 10.1111/1759-7714.13025. Epub 2019 Mar 22. Thorac Cancer. 2019. PMID: 30900826 Free PMC article.
EGFR Tyrosine Kinase Inhibitor (TKI) Combined With Concurrent or Sequential Chemotherapy for Patients With Advanced Lung Cancer and Gradual Progression After First-Line EGFR-TKI Therapy: A Randomized Controlled Study.
Chang Q, Xu J, Qiang H, Teng J, Qian J, Lv M, Zhang Y, Lou Y, Zhao Y, Zhong R, Han B, Chu T. Chang Q, et al. Among authors: qian j. Clin Lung Cancer. 2021 May;22(3):e395-e404. doi: 10.1016/j.cllc.2020.06.005. Epub 2020 Jul 6. Clin Lung Cancer. 2021. PMID: 32747190 Clinical Trial.
8,227 results